Targeting G4s at oncogene promoters could also be of interest for cancer therapy, and G4 ligands binding the c-MYC promoter or telomeric G4s were shown to downregulate both the c-MYC and hTERT gene expression, while upregulating γ-H2AX and 53BP1 due to DNA damage, yielding in vivo antitumor effect in tumor-engrafted mice [162]. This evidence concerns the gene MYC and cancer.